Voyager Therapeutics Company Profile

09:12 EST 17th December 2018 | BioPortfolio

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass. For more information, please visit

News Articles [725 Associated News Articles listed on BioPortfolio]

Sanofi’s Andre Turenne Is Slated to Become Voyager Therapeutics CEO

Voyager Therapeutics (NASDAQ: VYGR) has appointed Andre Turenne to serve as president and CEO of the Cambridge, MA-based gene therapy developer. Turenne will succeed Steven Paul, who is retiring but w...

Voyager Therapeutics, Brammer Bio, Fujifilm Diosynth Enter Mfg. Tie-up

Collaborations to provide Voyager the ability and flexibility to transfer its mfg. capabilities across multiple vendors

Ablexis grants Voyager AlivaMab Mouse rights for neurological diseases

Ablexis LLC granted Voyager Therapeutics Inc. a nonexclusive license to use its AlivaMab Mouse platform for the discovery, development, and commercialization of antibody therapeutics.

Appointments: New CEOs For Lundbeck, Voyager & Neos, CSOs For iTeos & Tilos

Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics...   

Voyager doses first patient in Phase II trial of VY-AADC

Voyager Therapeutics has dosed the first patient in the Phase II RESTORE-1 trial assessing the safety and efficacy of VY-AADC...Read More... The post Voyager doses first patient in Phase II trial of V...

Voyager's Parkinson's disease drug nabs FDA RMAT status

Voyager Therapeutics' drug candidate VY-AADC, being developed to treat patients with Parkinson's disease whose motor fluctuat -More- 

Voyager taps Brammer and Fujifilm for gene therapy development program

The clinical-stage gene therapy company Voyager Therapeutics has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to expand its manufacturing capabilities.

Karuna Names Former Voyager, Lilly Exec Steven Paul New CEO

Former Voyager Therapeutics (NASDAQ: VYGR) CEO Steven Paul has been tapped to run Boston-based Karuna Pharmaceuticals, a PureTech Health company that just raised $42 million this month. Karuna is deve...

PubMed Articles [461 Associated PubMed Articles listed on BioPortfolio]

Günter Blobel: a voyager of the cell.

Comparing a novel equation for calculating low-density lipoprotein cholesterol with th3e Friedewald equation: A VOYAGER analysis.

Treating elevated low-density lipoprotein cholesterol (LDL-C) to risk-stratified target levels is recommended in several guidelines. Thus, accurate estimation of LDL-C is required. LDL-C is typically ...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Clinical Trials [169 Associated Clinical Trials listed on BioPortfolio]

Nativis Voyager for Newly Diagnosed GBM

This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 11 subjects and will be combined w...

A Feasibility Study of the Nativis Voyager™ System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy. The study...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study

The purpose of this study is to compare improvement percentage of urinary albumin excretion between valsartan 80 mg- and valsartan 160 mg-based therapy in patient with morning hypertension...

Companies [1292 Associated Companies listed on BioPortfolio]

Voyager Therapeutics, Inc.

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advanc...

Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to...

Voyager Pharmaceutical Corp.

Voyager Pharmaceutical Corporation MissionVoyager Pharmaceutical Corporation embraces bold ideas and novel approaches to achieve…Cures for Mankind. Challenges & Rewards for every member of our team....

Yardi Systems

Yardi Systems has been committed to the design, development, and support of innovative software solutions for nearly 30 years. With the products comprising its Yardi Voyage...

Yardi Systems Inc.

Yardi Systems has been committed to the design, development and support of innovative software solutions for 30 years. With its senior housing software and investment management s...

More Information about "Voyager Therapeutics" on BioPortfolio

We have published hundreds of Voyager Therapeutics news stories on BioPortfolio along with dozens of Voyager Therapeutics Clinical Trials and PubMed Articles about Voyager Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Voyager Therapeutics Companies in our database. You can also find out about relevant Voyager Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Corporate Database Quicklinks

Searches Linking to this Company Record